利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.071 秒)

    Methods and compositions for identification and therapeutic use of genes involved in vascular and proliferative diseases
    27.
    发明申请
    Methods and compositions for identification and therapeutic use of genes involved in vascular and proliferative diseases 审中-公开
    用于鉴定和治疗使用涉及血管和增殖性疾病的基因的方法和组合物

    公开(公告)号：US20050118564A1

    公开(公告)日：2005-06-02

    申请号：US10500769

    申请日：2003-01-31

    申请人： Sivaram Pillarisetti ,  Uday Saxena

    发明人： Sivaram Pillarisetti ,  Uday Saxena

    IPC分类号： C07H21/04 ,  C12Q1/00 ,  C12Q1/68 ,  G01N20060101 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： The present invention comprises compositions and methods for identification of genes involved in vascular diseases using human endothelial and smooth cell “artery wall” models to capture the cell-cell and cell-matrix communications that are operative in normal and diseases conditions. The present invention further comprises the capture of the complexity of multiple chronic pathologies that coexist in humans by simultaneous treatment of the cells with disease specific stimuli and the identification and use of genes that are regulated by such multiple established disease mediators. The present invention additionally comprises compositions and methods of treatment of vascular disease.

    摘要翻译： 本发明包括使用人内皮和光滑细胞“动脉壁”模型鉴定参与血管疾病的基因的组合物和方法，以捕获在正常和疾病状况下操作的细胞 - 细胞和细胞 - 基质通讯。 本发明还包括通过用疾病特异性刺激同时治疗细胞以及鉴定和使用由这种多种既定疾病介质调节的基因来捕获人类共存的多种慢性病理学的复杂性。 本发明另外包括治疗血管疾病的组合物和方法。

    Methods and compositions for the treatment of inflammatory diseases
    28.
    发明授权
    Methods and compositions for the treatment of inflammatory diseases 失效
    用于治疗炎性疾病的方法和组合物

    公开(公告)号：US06900041B2

    公开(公告)日：2005-05-31

    申请号：US09969013

    申请日：2001-10-02

    申请人： Shianlen Cahoon ,  Sivaram Pillarisetti ,  Uday Saxena ,  Angela Vines

    发明人： Shianlen Cahoon ,  Sivaram Pillarisetti ,  Uday Saxena ,  Angela Vines

    IPC分类号： A61P29/00 ,  C12Q1/48 ,  C12Q1/68 ,  C12N9/12 ,  G01N33/53

    CPC分类号： C12Q1/485 ,  C12Q1/6897 ,  G01N2333/91215

    摘要： The present invention is directed to compositions and methods for treating inflammatory diseases comprising administration of compositions that effect glycogen synthase kinase 3β (GSK-3β) protein or gene. The present invention also comprises methods and compositions for the identification of compounds or therapeutic agents which modulate the activity of the protein. The present invention provides compositions for and methods off treatment of biological conditions including, but not limited to, type I and type II diabetic induced vasculopathy, other vasculopathies, asthma and inflammation-induced diseases such as atherosclerosis and cell proliferation.

    摘要翻译： 本发明涉及用于治疗炎性疾病的组合物和方法，包括施用影响糖原合酶激酶3β（GSK-3β）蛋白或基因的组合物。 本发明还包括用于鉴定调节蛋白质活性的化合物或治疗剂的方法和组合物。 本发明提供了生物学条件的组合物和方法，包括但不限于I型和II型糖尿病诱发的血管病变，其它血管病变，哮喘和炎性引起的疾病如动脉粥样硬化和细胞增殖。

    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA
    30.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA 审中-公开
    用于治疗糖尿病和DYSLIPIDEMIA的方法和组合物

    公开(公告)号：US20140121267A1

    公开(公告)日：2014-05-01

    申请号：US14148572

    申请日：2014-01-06

    申请人： Ish Khanna ,  Sivaram Pillarisetti

    发明人： Ish Khanna ,  Sivaram Pillarisetti

    IPC分类号： C07C311/51

    CPC分类号： C07C311/51 ,  A61K31/18 ,  A61K31/255 ,  C07C2601/02 ,  C07D257/04

    摘要： Novel compounds of Formula A1 are provided: its stereoisomers and/or pharmaceutically acceptable salts for the treatment of diabetes and diabetes-associated dyslipidemia, wherein R7 is independently selected from a group consisting of hydroxy, alkoxy, alkyl, amine, NHR′ wherein R′ is alkyl or cycloalkyl optionally substituted by hydroxy or alkoxy, NHSO2R or NHCOR, wherein R is selected from alkyl or cycloalkyl. At least one of R3 and R4 and/or R5 and R6 form a cyclic ring of 3-8 carbon atoms optionally containing alkyl groups, hetero atoms, or functional groups such as O, N, SO2. Additionally R3 and R4 or R5 and R6, when they do not form a cyclic ring, are independently selected from hydrogen, alkyl, branched alkyl, and cycloalkyl. L1 is independently a linear aliphatic chain optionally containing from 6 to 16 carbon-atoms and L1 may optionally be substituted one or more times by alkyl, branched alkyl, cycloalkyl, or aryl.

    摘要翻译： 提供式A1的新型化合物：其用于治疗糖尿病和糖尿病相关血脂异常的其立体异构体和/或药学上可接受的盐，其中R 7独立地选自羟基，烷氧基，烷基，胺，NHR'，其中R' 是任选被羟基或烷氧基取代的烷基或环烷基，NHSO 2 R或NHCOR，其中R选自烷基或环烷基。 R3和R4和/或R5和R6中的至少一个形成任选含有烷基，杂原子或官能团如O，N，SO 2的3-8个碳原子的环。 另外，当它们不形成环时，R 3和R 4或R 5和R 6独立地选自氢，烷基，支链烷基和环烷基。 L1独立地是任选含有6至16个碳原子的直链脂族链，并且L 1可以任选被烷基，支链烷基，环烷基或芳基取代一次或多次。